Review Article

Hyperbilirubinemia in Neonates: Types, Causes, Clinical Examinations, Preventive Measures and Treatments: A Narrative Review Article

Abstract

Background: Hyperbilirubinemia, or jaundice, is a life threatening disorder in newborns. It is a multifactorial disorder with many symptoms. Generally, the physiological jaundice is the most prevalent type however in some regions pathological jaundice is also common. This review article focuses on a brief introduction to jaundice, its types and causes, measuring the bilirubin level, clinical approaches towards hyperbilirubinemia, different precautionary measures for the parents of babies suffering from hyperbilirubinemia and different remedial therapeutic measures for its treatment.

Methods: The main databases including Scopus, Pubmed, MEDLINE, Google scholar and Science Direct were researched to obtain the original papers related to the newborns’ hyperbilirubinemia. The main terms used to literature search were newborns’ hyperbilirubinemia”, “newborns’ jaundice”, “Physiological Jaundice” and “Patholigical Jaundice”. The timeframe included the obtained articles was from 1952 to 2015.   

Results: Neonatal jaundice due to breast milk feeding is also sometimes observed. Hemolytic jaundice occurs because of the incompatibility of blood groups with ABO and Rh factors, when the fetus and mother blood groups are not compatible and the fetus blood crosses the barrier of the umbilical cord before birth causing fetus blood hemolysis owing to severe immune response.

Conclusion: Jaundice is easily diagnosable however require quick and on the spot treatment. If not treated properly, it leads to many complications. Currently the treatment options for jaundice include photo therapy, chemotherapy, and vaccinations.

 

 

Olusanya BO, Osibanjo FB, Slusher TM (2015). Risk factors for severe neonatal hyperbiliru¬binemia in low and middle-income countries: a systematic review and meta-analysis. PLoS One, 10(2): e0117229.

Bhutani VK, Zipursky A, Blencowe H, Khanna R, Sgro M, Ebbesen F (2013). Neonatal hyper¬bilirubinemia and Rhesus disease of the new¬born: incidence and impairment estimates for 2010 at regional and global levels. Pediatr Res, 1:86-100.

American Academy of Pediatrics Practice Pa-ram¬eter (1994). Management of hyperbili-ru¬binemia in the healthy term newborn. Pediatrics, 94: 558-65.

Burke BL, Robbins JM, Bird TM, Hobbs CA, Nesmith C, Tilford JM (2009). Trends in hos¬pitalizations for neonatal jaundice and kernic¬terus in the United States, 1988–2005. Pediat¬rics, 123: 524–32.

Young Infants Clinical Signs Study Group (2008). Clinical signs that predict severe illness in chil¬dren under age 2 months: a multicentre study. Lancet, 371(9607): 135-42.

Chou RH, Palmer RH, Ezhuthachan S, et al. (2003). Management of hyperbiliru-binemia in newborns: measuring perfor-mance by using a benchmarking model. Pediatrics, 112:1264–73.

Ogunfowora OB, Daniel OJ (2006). Neona-tal jaundice and its management: Knowledge, at¬titude and practice of community health work¬ers in Nigeria. BMC Public Health, 6:19.

Schneider AP (1986). Breast milk jaundice in the newborn: A real entity. JAMA, 255(23): 3270-74.

Nag N, Halder S, Chaudhuri R, Adhikary S, Ma¬zumder S (2009). Role of bilirubin as antioxi¬dant in neonatal jaundice and ef-fect of etha¬nolic extract of sweet lime peel on experimen¬tally induced jaundice in rat. Indian J Biochem Biophys, 46:73–78.

Yousefi M, Rahimi H, Barikbin B, Toossi P, Lotfi S, Hedayati M, et al (2011). Uric ac-id: a new antioxidant in patients with pemphigus vul¬garis. IJD, 56(3): 278–281.

Barikbin B, Yousefi M, Rahimi H, Hedayati M, Razavi SM, Lotfi S (2011). Antioxidant status in patients with lichen planus. Clin Exp Dermatol, 36(8): 851–54.

Paludetto R, Mansi G, Raimondi F, Romano A, Crivaro V, Bussi M, D’Ambrosio G (2002). Moderate hyperbilirubinemia in-duces a transi¬ent alteration of neonatal behavior. Pediatrics, 110: e50.

Boo NY, Ishak S (2007). Prediction of se-vere hy¬perbilirubinaemia using the Bili-check transcutaneous bilirubinometer. J Paediatr Child Health, 43: 297-302.

Nass RD, Frank Y (2010). Cognitive and Behav-ioral Abnormalities of Pediatric Diseases. 1st ed. Oxford University Press.

Gartner LM, Lee KS (1999). Jaundice in the breast-fed infant. Clin Perinatol, 26:431-45.

Mesic I, Milas V, Medimurec M, Rimar Z (2014). Unconjugated pathological jaun-dice in new¬borns. Coll Antropol, 38(1): 173-8.

D'Silva S, Colah RB, Ghosh K, Mukherjee MB (2014). Combined effects of the UGT1A1 and OATP2 gene polymor-phisms as major risk factor for unconju-gated hyperbilirubinemia in Indian neo-nates. Gene, 547(1):18-22.

Huang MJ, Kua KE, Teng HC, Tang KS, Weng HW, Huang CS (2004). Risk factors for severe hyperbilirubinemia in neonates. Pediatr Res, 56(5):682-9.

Watchko JF, Lin Z (2010). Exploring the genetic architecture of neonatal hyperbili-rubinemia. Semin Fetal Neonatal Med, 15:169–175.

Xu LY, He YJ, Zhang W, Deng S, Li Q, Zhang WX, et al. (2007). Organic anion transporting polypeptide-1B1 haplotypes in Chinese pa¬tients. Acta Pharmacol Sin, 28:1693–97.

Tirona RG, Leake BF, Merino G, and Kim RB (2001). Polymorphisms in OATP-C: identifi¬cation of multiple allelic variants associated with altered transport activity among Euro¬pean- and African-Americans. J Biol Chem, 276:35669–35675.

Sanna S, Busonero F, Maschio A, McArdle PF, Usala G, Dei M, et al (2009). Com-mon variants in the SLCO1B3 locus are associated with bilirubin levels and un-conjugated hyper¬bilirubinemia. Hum Mol Genet, 18:2711–8.

Alencastro de Azevedo L, Reverbel da Silvei-ra T, Carvalho CG, Martins de Castro S, Giugliani R, Matte U (2012). UGT1A1, SLCO1B1, and SLCO1B3 polymor-phisms vs. neonatal hyper¬bilirubinemia: is there an association? Pediatr Res, 72(2):169-73.

Mishra S, Agarwal R, Deorari AK, Paul VK (2008). Jaundice in the newborns. Indian J Pedi¬atr, 75(2): 157-163.

Boyd S (2004). Treatment of physiological and pathological neonatal jaundice. Nurs Times, 100(13): 40-43.

Clarkson JE, Cowan JO, Herbison GP (1984). Jaundice in full term healthy neo-nates: A pop¬ulation study. Aust Paediatr J, 20:303-8.

Dennery PA, Seidman DS, Stevenson DK (2001). Neonatal hyperbilirubinemia. NEJM, 344(8): 581-290.

Maisels MJ, Gifford K (1983). Neonatal jaundice in full-term infants. Role of breastfeeding and other causes. AJDC, 137:561–2.

Alcock GS, Liley H (2002). Immunoglobulin in¬fusion for isoimmune haemolytic jaun-dice in neonates. CDSR, 3: CD003313.

Atkinson LR, Escobar GJ, Takyama, JI, Newman TB (2003). Phototherapy use in jaundiced newborns in a large managed care organiza¬tion: do clinicians adhere to the guideline? Pedi¬atrics, 111: e555-61.

Hansen TW (2003). Recent advances in the phar¬macotherapy for hyperbilirubinemia in the ne¬onate. Expert Opin Pharmacother, 4(11): 1939-1948.

Winfield CR, MacFaul R (1978). Clinical study of prolonged jaundice in breast and bottle fed ba¬bies. Arch Dis Child, 53: 506-7.

Kramer LI (1969). Advancement of dermal ic¬terus in jaundiced newborn. AJDC, 118: 454-8.

Shapiro-Mendoza C (2006). Risk factors for neo¬natal morbidity and mortality among “healthy” late preterm newborns. Semin Perinatol, 30: 54-60.

Dennery PA (2002). Pharamacological inter-ven¬tions for the treatment of neonatal jaundice. Semin Neonatol, 7: 111-119.

Maruo Y, Nishizawa K, Sato H, Sawa H, Shimada M (2000). Prolonged unconju-gated hyperbili¬rubinemia associated with breast milk and mu¬tations of the bilirubin uridine diphosphate- glucuronosyltrans-ferase gene. Pediatrics, 106(5): E59.

Maisels MJ (1998). Jaundice. In: Taeugah, H.W., Ballard, R.A. and Avery, M.E. (eds). Schaffers and Avery’s Diseases of New-born (7th ed.). Philadelphia: WB Saunders Company. pp. 603-708.

Al-Swaf FB, Jumaa RS, Saeed IS (2009). He-mo¬lytic disease of newborn due to ABO incom¬patibility. Tikrit Medical Journal, 15(2): 70-78.

Stockman, JA (2001). Overview of the state of the art of Rh disease: history, current clinical man¬agement, and recent progress. J Pediatr Hematol Oncol, 23(8):554-62.

Bowman J (2003). Thirty-five years of Rh prophy¬laxis. Transfusion, 43:1661-6.

Van Kamp IL, Klumper FJ, Oepkes D, Meerman RH, Scherjon SA, Vanden-bussche FP, et al (2005). Complications of intrauterine intravas¬cular transfusion for fetal anemia due to mater¬nal red-cell alloimmunization. Am J Obstet Gynecol, 192(1): 171-7.

Murray NA, Roberts IA (2007). Haemolytic dis¬ease of the newborn. ADC Fetal Neo-natal Ed, 92: 83-8.

Yigit S, Gursoy T, Kanra T, et al (2005). Whole blood versus red cells and plasma for exchange transfusion in ABO haemo-lytic disease. Transfus Med, 15: 313-8.

Yaseen H, Khalaf M, Rashid N, Darwich M (2005). Does prophylactic phototherapy pre¬vent hyperbilirubinemia in neonates with ABO incompatibility and positive Coombs' test? J Perinatol, 25: 590-4.

Kaplan M, Na'amad M, Kenan A, Rudensky B, Hammerman C, Vreman HJ, Wong RJ, Ste¬venson DK (2009). Failure to pre-dict hemoly¬sis and hyperbilirubinemia by IgG subclass in blood group A or B in-fants born to group O mothers. Pediatrics, 123(1): e132-7.

Moiz B, Nasir A, Khan SA, Kherani SA, Qadir M (2012). Neonatal hyperbiliru-binemia in infants with G6PD c.563C > T variant. BMC Pediatrics, 12: 126-133.

Marzban A, Mosavinasab N (2008). Correla-tion between hemolysis and jaundice in Glucose 6-Phosphate Dehydrogenase de-ficient neonates. Acta Medica Iranica, 47(5): 379-83.

Kaplan M, Hammerman C (1998). Severe neona¬tal hyperbilirubinemia. A potential complica¬tion of glucose-6-phosphate de-hydrogenase deficiency. Clin Perinatol, 25(3): 575-90.

Bhutani VK, Johnson L, Sivieri ME (1999). Pre¬dictive ability of a predischarge hour-specific serum bilirubin for subsequent significant hy¬perbilirubinemia in healthy term and near-term newborns. Pediatrics, 103(1): 6-16.

Cashore WJ (2000). Bilirubin and jaundice in the micropremie. Clin Perinatol, 27: 171-9.

Johnson L, Bhutani VK (1998). Guidelines for management of the jaundiced term and near term infant. Clin Perinatol, 25: 555-574.

Watson D, Rogers JA (1961). A study of six rep¬resentative methods of plasma biliru-bin analy¬sis. J Clin Pathol, 14: 271-8.

Yamanouchi I, Yamauchi Y, Igarashi I (1980). Transcutaneous bilirubinometry: preliminary studies of noninvasive transcutaneous biliru¬bin meter in the Okayama National Hospital. Pediatrics, 65:195–202.

Maisels MJ, Ostrea EM, Touch S, Clune SE, Cepeda E, Kring E, et al (2004). Evalua-tion of a new transcutaneous bilirubin-ometer. Pediat¬rics, 113: 1628–35.

Gohmann K, Roser M, Rolinski B, Kadow I, Muller C, Goerlach-Graw A, et al (2006). Bili¬rubin measurement for neo-nates: Comparison of 9 frequently used methods. Pediatrics, 117(4):1174-83.

Puppalwar PV, Goswami K, Dhok A (2012). Re¬view on “Evolution of Methods of Bil-irubin Estimation”. IOSR-JDMS, 1(3): 17-18.

Royal Prince Alfred Hospital (2003). Haemo-lytic jaundice, Rhesus isoimmunization. RPA New¬born care guidelines: Royal Prince Alfred Hos¬pital, Sydney Australia.

Bosschaart N, Kok JH, Newsum AM, Ouwenee DM, Mentink R, van Leeuwen TG, et al (2012). Limitations and oppor-tunities of transcutaneous bilirubin meas-urement. Pediat¬rics, 129: 689-97.

Krishnasamy M, Bakri DR (2009). Non-invasive, hand held transcutaneous biliru-binometer. Medical Development Divi-sion, Ministry of Health, Malaysia.

Robertson A, Kazmierczak S, Vos P (2002). Im¬proved transcutaneous bilirubinome-try: com¬parison of SpectRx Bilicheck and Minolta jaundice meter JM-102 for esti-mating total se¬rum in a normal newborn population. J Perina¬tolo, 22(1):12–14.

American Academy of Pediatrics (2004b). Clinical Practice Guideline: Subcommittee on Hyper¬bilirubinemia, Management of Hyperbiliru¬binemia in the newborn infant 35 or more week of gestation. Pediatrics, 114(1): 297-316.

Watchko JF, Maisels MJ (2003). Jaundice in low birth weight infants: pathobiology and out¬come. Arch Dis Child Fetal Neonatal Ed, 88: F455-8.

Okwundu CI, Okoromah CAH, Shah PS (2012). Prophylactic phototherapy for preventing jaundice in preterm or low birth weight infants. Cochrane Database Syst Rev, 2012(1): CD007966.

Maisels MJ, Watchko JF, Bhutani VK, Ste-venson DK (2012). An approach to the management of hyperbilirubinemia in the preterm infant less than 35 week of gesta-tion. J Perinatol, 32: 660-4.

Frank JE (2005). Diagnosis and manage-ment of G6PD deficiency. Am Fam Physi-cian, 72(7): 1277-1282.

Engle WD, Jackson GL, Sendelbach D, Manning D, Frawley W (2002). Assess-ment of a transcutaneous device in the evaluation of ne¬onatal hyperbilirubinemia in a primarily His¬panic population. Pediat-rics, 110: 61–67.

Schumacher R (2002). Transcutaneous bili-rubin¬ometry and diagnostic tests: “the right job for the tool.” Pediatrics, 110: 407–408.

Ip S, Glicken S, Kulig J, Obrien R, Sege R, Lau J (2003). Management of Neonatal Hyper-biliru¬binemia. Rockville, MD: US Depart-ment of Health and Human Services, Agency for Healthcare Research and Quality. AHRQ Publication 03-E011.

Kappas A, Drummond GS, Munson DP, Mar¬shall JR (2001). Sn-mesoporphyrin interdiction of severe hyperbilirubinemia in Jehovah’s Wit¬ness newborns as an al-ternative to exchange transfusion. Pediat-rics, 108: 1374–7.

Ennever JF (1990). Blue light, green light, white light, more light: treatment of neo-natal jaun¬dice. Clin Perinatol, 17:467–81.

Cremer RJ, Perryman RW, Richards DH (1958). Influence of light on the hyperbili-rubinaemia of infants. Lancet, 1:1094-7.

Brown AK, Kim MH, Wu PY, Bryla DA (1985). Efficacy of phototherapy in pre-vention and management of neonatal hy-perbilirubinemia. Pediatrics, 75: 393–400

Vecchi C, Donzelli GP, Migliorini MG, Sbrana G (1983). Green light in photo-therapy. Pediatr Res, 17:461-3.

Tan KL (1989). Efficacy of fluorescent day-light, blue, and green lamps in the man-agement of nonhemolytic hyperbiliru-binemia. J Pediatr, 114:132-7.

Tan KL (1991). Phototherapy for neonatal jaun¬dice. Clin Perinatol, 18: 423-39.

Amato M, Howald H, von Muralt G (1985). In¬terruption of breast-feeding versus photother¬apy as treatment of hyperbiliru-binemia in full-term infants. Helvetica Pae-diatrica Acta, 40:127–31.

Caldera R, Maynier M, Sender A, Brossard Y, Tortrat D, Galiay JC, Badoual J (1993). The effect of human albumin in associa-tion with in¬tensive phototherapy in the management of neonatal jaundice. Arch Fr Pediatr, 50: 399-402.

Maisels MJ (2001). Phototherapy—traditional and nontraditional. J Perinatol, 21(suppl 1): S93–7.

Seidman DS, Moise J, Ergaz Z, Laor A, Vreman HJ, Stevenson DK, Gale R (2000). A new blue light-emitting photo-therapy device: A prospec¬tive randomized controlled study. J Pediatr, 136(6): 771-4.

Harris M, Bernbaum J, Polin J, Zimmerman R, Polin RA (2001). Developmental fol-low-up of breastfed term and near-term infants with marked hyperbilirubinemia. Pediatrics, 107: 1075–1080.

American Academy of Pediatrics (2004a). Sub¬committee on Hyperbilirubinemia. Manage¬ment of hyperbilirubinemia in the newborn in¬fant 35 or more week of ges-tation. Pediatrics, 114 (3): 297–316.

Royal Prince Alfred Hospital (2006). Trans-cutene¬ous bilirubinometers. RPA New-bon care guidelines, Royal Prince Alfred Hospital, Syd¬ney Australia.

Hsia DYY, Allen FH, Gelliss SS, Drum-mond LK (1952). Erythroblastosis fetalis, VIII: studies of serum bilirubin in relation to kernicterus. N Engl J Med, 247:668-71.

Mollison PL, Cutbush M (1954). Haemolytic disease of the newborn. In: Gairdner D, ed. Recent Ad¬vances in Pediatrics. New York, NY: P Bla¬kiston & Son, pp: 110.

Gabilan JC (1998). Pharmacologic treatment of neonatal jaundice. A new approach. Archives de Pediatrie, 5(11): 1274-8.

Cuperus FJ, Hafkamp AM, Hulzebos CV, Verkade HJ (2009). Pharmacological ther-apies for unconjugated hyperbiliru-binemia. Curr Pharm Des, 15(25): 2927-38.

Kaseem LM, Abdelrahim MEA, Naguib HF (2013). Investigating the Efficacy and Safety of Silymarin in Management of Hyperbiliru¬binemia in Neonatal Jaundice. Med Sci, 2(2): 575-590.

Valaes T, Petmezaki S, Henschke C, Drum-mond GS, Kappas A (1994). Control of jaundice in preterm newborns by an in-hibitor of bilirubin production: studies with tin-mesoporphyrin. Pediatrics, 93(1): 1–11.

Marie S, Cresteil T (1989). Phenobarbital-induci¬ble gene expression in developing rat liver: re¬lationship to hepatocyte func-tion. Biochimica et Biophysica Acta, 1009(3): 221–8.

Shankaran S, Papile LA, Wright LL, Eh-renkranz RA, Mele L, Lemons JA, et al (1997). The ef¬fect of antenatal phenobar-bital therapy on ne¬onatal intracranial hemorrhage in preterm in¬fants. N Engl J Med, 337(7): 466–471.

Shankaran S, Woldt E, Nelson J, Bedard M, Delaney-Black V (1996). Antenatal phe-nobar¬bital therapy and neonatal outcome. II: Neuro¬developmental outcome at 36 months. Pediat¬rics, 97(5): 649–52.

Hansen TW, Tommarello S (1998). Effect of phe¬nobarbital on bilirubin metabolism in rat brain. Biol Neonate, 73(2): 106–11.

Crowther CA, Henderson-Smart DJ (2001). Phe¬nobarbital prior to preterm birth for prevent¬ing neonatal periventricular haem-orrhage. Cochrane Database Syst Rev, 2001 ;(2):CD000164.

Whitelaw A (2001). Postnatal phenobarbi-tone for the prevention of intraventricular hemorrhage in preterm infants. Cochrane Database Syst Rev, 2001 ;(1):CD001691.

Sato K, Hara T, Kondo T, Iwao H, Honda S, Ueda K (1991). High-dose intravenous gam¬maglobulin therapy for neonatal im-mune hae¬molytic jaundice due to blood group incom¬patibility. Acta Paediatr Scand, 80: 163–6.

Rubo J, Albrecht K, Lasch P, Laufkotter E, Leiti¬tis J, Marsan D, et al (1992). High-dose intra¬venous immune globulin thera-py for hyperbili¬rubinemia caused by Rh hemolytic disease. J Pediatr, 121: 93–7.

Ergaz Z, Arad I (1993). Intravenous immu-no¬globulin therapy in neonatal immune hemo¬lytic jaundice. J Perinat Med, 21(3): 183-7.

Hammerman C, Kaplan M, Vreman HJ, Steven¬son DK (1996). Intravenous im-mune globulin in neonatal ABO isoim-munization: factors as¬sociated with clini-cal efficacy. Biol Neonate, 70: 69–74.

Alpay F, Sarici SU, Okutan V, Erdem G, Ozcan O, Gokc¸ay E (1999). High-dose intravenous immunoglobin therapy in neonatal immune haemolytic jaundice. Ac-ta Paediatrica, 88: 216–219.

Girish G, Chawla D, Agarwal R, Paul VK, Deo¬rari AK (2008). Efficacy of two dose regimes of intravenous immunoglobulin in Rh hemo¬lytic disease of newborn – a randomized con¬trolled trial. Indian Pediat-rics, 45: 653-9.

Smits-Wintjens VE, Walther FJ, Rath ME, Lin¬denburg IT, te Pas AB, Kramer CM, Oepkes D, Brand A, Lopriore E (2011). Intravenous immunoglobulin in neonates with rhesus he¬molytic disease: a random-ized controlled trial. Pediatrics, 127: 680–6.

Cortey A, Elzaabi M, Waegemans T, Roch B, Aujard Y (2014). Efficacy and safety of intra¬venous immunoglobulins in the management of neonatal hyperbiliru-binemia due to ABO in¬compatibility: a meta-analysis. Archives de Pedia¬trie, 21(9): 976-83.

Qato MK, Maines MD (1985). Preven-tion of ne¬onatal hyperbilirubinaemia in non-human pri¬mates by Znprotoporphy-rin. Biochem J, 226(1): 51–7.

Vreman HJ, Ekstrand BC, Stevenson DK (1993). Selection of metalloporphyrin heme oxygen¬ase inhibitors based on po-tency and photore¬activity. Pediatr Res, 33(2): 195–200.

Kappas A, Drummond GS, Henschke C, Valaes T (1995). Direct comparison of Sn-mesopor¬phyrin, an inhibitor of biliru-bin production, and phototherapy in controlling hyperbiliru¬binemia in term and near-term newborns. Pedi¬atrics, 95(4): 468–74.

Valaes T, Drummond GS, Kappas A (1998). Control of hyperbilirubinemia in glucose-6-phosphate dehydrogenasede-ficient newborns using an inhibitor of bil-irubin production, Sn-mesoporphyrin. Pediatrics, 101(5): E1.

Martinez JC, Garcia HO, Otheguy LE, Drum¬mond GS, Kappas A (1999). Con-trol of severe hyperbilirubinemia in fullterm newborns with the inhibitor of bilirubin production Sn-meso¬porphyrin. Pediatrics, 103(1): 1–5.

Facchini FP, Mezzacappa MA, Rosa IRM, Filho FM, Netto AA, Marba STM (2007). Follow-up of neonatal jaundice in term and late premature newborns. J Pediatr (Rio J), 83(4): 313-8.

Sharma P, Chhangani NP, Meena KR, Jora R, Sharma N, Gupta BD (2006). Brainstem Evoked Response Audiometry (BAER) in Ne¬onates with Hyperbiliru-binemia. Indian J Pedi¬atr, 73 (5): 413-6.

Bhutani VK (2012). Jaundice Due to Glu-cose-6-Phosphate Dehydrogenase Defi-ciency. Neo Rev, 13(3): e166-79.

Kuboi T, Kusaka T, Kawada K, Koyano K, Nakamura S, Okubo K, et al (2013). Hour-spe¬cific nomogram for transcuta-neous bilirubin in Japanese neonates. Pe-diatr Int, 55: 608-11.

Files
IssueVol 45 No 5 (2016) QRcode
SectionReview Article(s)
Published2016-05-25
Keywords
Hyperbilirubinemia Immunoglobulin Bilirubinometer Exchange transfusion

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
1.
ULLAH S, RAHMAN K, HEDAYATI M. Hyperbilirubinemia in Neonates: Types, Causes, Clinical Examinations, Preventive Measures and Treatments: A Narrative Review Article. Iran J Public Health. 45(5):558-568.